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Research articlePrimary gamma-herpesviral infection in Zambian 
children
Veenu Minhas1, Brad P Brayfield1, Kay L Crabtree1, Chipepo Kankasa2, Charles D Mitchell3 and Charles Wood*1
Abstract
Background: HHV-8 is closely related to Epstein-Barr virus (EBV), but the clinical presentations of these two infections 
in early childhood are not well understood. Also, it is not known whether infection by one virus correlates with another. 
Here, we compare the natural history of infection by these two viruses along with the clinical manifestations and risk 
factors that are associated with early childhood infection in Zambia, which is an endemic area for HHV-8.
Methods: This study was conducted in a cohort of 12 month old Zambian children (N = 677). Data on socio-economic 
status and a wide range of clinical manifestations were collected. Logistic regression was used to test for significant 
associations between the collected variables and HHV-8 or EBV serostatus at 12 months of age.
Results: We observed a significantly higher seroprevalence for EBV (58.9%) as compared to HHV-8 (13.4%). HIV-1 
infected children had at a significantly higher risk of being infected with HHV-8 (Odds ratio [OR] 3.69, 95% confidence 
interval [CI] 1.64 - 8.32). HIV-1 infection of the mothers was a significant risk factor for increased acquisition of EBV but 
not HHV-8 by children (OR 1.86, 05% CI 1.20 - 2.87). Self reported rash was marginally associated with primary infection 
for HHV-8 and EBV.
Conclusions: These results suggest that there is no correlation between EBV and HHV-8 infections. Infection by one 
does not increase the susceptibility for the second virus. Primary HHV-8 and EBV infection in early childhood may 
clinically present as rash but remains largely asymptomatic and may remain undetected in this population. HIV 
infection in the mother or child are important risk factors that contribute to EBV or HHV-8 infection.
Background
Human herpesvirus-8 (HHV-8), also known as Kaposi's
sarcoma-associated herpesvirus (KSHV) is a gamma-her-
pesvirus reported to be associated with all forms of
Kaposi's sarcoma (KS) [1,2]. HHV-8 is closely related to
Epstein-Barr virus (EBV), the only other known human
gamma-herpesvirus with both having a latent and lytic
phase of replication. EBV is the most commonly identi-
fied virus associated with AIDS-related non-Hodgkin
lymphomas, CNS lymphomas, African Burkitt's Lym-
phoma, and Nasopharyngeal Carcinoma [3,4]. HIV-asso-
ciated immunosuppression has led to an increase in the
incidence of childhood Kaposi's sarcoma and non-Hodg-
kin lymphomas including African Burkitt's lymphoma in
sub-Saharan Africa [5].
Little is known about the acquisition of HHV-8 and
EBV in early childhood in endemic African countries like
Zambia especially after the onset of the HIV-1 epidemic
in this region. Whether infection by one virus enhances
the susceptibility to infection by the other in the context
of HIV-1 infection and immune-suppression is not
known. Most studies that documented the prevalence of
HHV-8 have sampled a cross-section of the population.
These studies have reported various factors that are asso-
ciated with increased risk for HHV-8 prevalence but not
on primary HHV-8 infection and the associated clinical
symptoms. In addition, it is still not clear whether pri-
mary infection with HHV-8 produces an acute clinical
syndrome and what factors increase the risk of acquisi-
tion of HHV-8 and EBV. Only one study conducted on
immunocompetent children in Egypt has reported that
primary HHV-8 infection may present itself as a febrile
illness and the infected children developed a maculopap-
ular rash [6]. Whether similar clinical symptoms are
observed in endemic areas such as Zambia and whether
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symptoms are similar for primary HHV-8 and EBV infec-
tions is still not known. As a part of our previous cohort
studies in Zambia, we recruited newborn infants and fol-
lowed them for up to 48 months of age. We have found
that approximately 40% of children became infected with
HHV-8 by 48 months of age [7]. Our cohort provided us
an opportunity to further investigate early childhood
infection in children less than 12 months of age. We
anticipate that children of this age group will most likely
undergo primary infection rather than reactivation of
latent infection. Due to the prospective design and data
collection during follow-up, our study provides a unique
opportunity to examine potential risks with these two
herpesviruses in the same population.
The objective of this study was to determine HHV-8
and EBV seroprevalence in the children, the effect of
HIV-1 infection, the specific clinical manifestations and
the risk factors involved. Here, we report the prevalence
of HHV-8 and/or EBV serostatus in 12 month old Zam-
bian children where primary infection event had
occurred. We also report the clinical symptoms during
the primary infection, the association of primary infec-
tion with the HIV-1 status of the child and analyze the
association of a positive serostatus at 12 months of age
with markers of social and economic status.
Methods
Study participants
Enrollment and follow-up- As described previously [7],
study participants were recruited as part of a prospective
cohort of mother/child pairs at the University Teaching
Hospital (UTH) in Lusaka, Zambia between October
1998 and April 2004. Women in the early stages of labor
and their newborn children were enrolled in a prospec-
tive cohort study after the mothers were counseled, edu-
cated about the study, and had given written informed
consent. The study was approved by the Institutional
Review Boards of the University of Zambia, University of
Nebraska, and University of Miami. A total of 1,424
mother-child pairs who returned for at least one post-
partum visit constituted our longitudinal cohort (Figure
1).
Inclusion and exclusion criteria
Among the cohort of 684 children of 12 months of age,
adequate amount of plasma for reliable testing for HHV-8
and EBV was not available for 7 children. Therefore, the
present analysis includes 677 children who survived and
were followed up till at least 24 months of age in order to
establish reliable HIV-1 status. Children who did not
return for a follow-up visit at age 24 months (n = 740)
were excluded from this analysis. Other reasons for
exclusion included early mortality, early withdrawal, and
loss to follow-up before HIV-1 serostatus could be reli-
ably established. Diagnostic PCR testing for HIV-1 in
children below 18 months of age was not available in
Zambia at the time of this study. Therefore, HIV-1 serol-
ogy was performed between 18 - 24 months of age. By 24
months of age, 6 percent (41/677) of the children tested
positive for HIV-1.
Serological testing
Blood specimens collected from children were coded by a
unique identification number and analyzed without
knowledge of the personal identity of the study partici-
pants. To rule out detection of transplacental maternal
HHV-8 antibodies, child plasma was not screened for
HHV-8 infection until the age of 12 months and for HIV-
1 infection until the age of 18 months.
HHV-8 serology
All plasma samples were tested by monoclonal-enhanced
immunofluorescence assay (mIFAs) as described previ-
ously [8]. Briefly, BC3 mIFAs were conducted by stimu-
lating BC-3 cells with tetradecanoyl phorbol acetate
(TPA), which were then fixed with 4% paraformaldehyde
and permeabilized after 72 hours. To reduce subjectivity
in observing specific fluorescence, slides were read inde-
pendently by two laboratory workers. All plasma deter-
mined to be positive by BC-3 mIFA was further
confirmed using Sf9 mIFA. Recombinant baculoviruses
expressing glutathione S-transferase tagged lytic pro-
teins, ORF65 and K8.1A, and latent protein, ORF73 were
used to develop Sf9 mIFAs. Baculovirus-infected Sf9 cells
expressing GST alone were used as a negative control to
detect background and nonspecific fluorescence. All
infections were initiated separately, to maximize the level
of proteins produced, harvested at 72 hpi and fixed using
the BC3 cell method. The procedure of Sf9 mIFA was the
same as that for BC3 mIFA. A sample was considered
seropositive for HHV-8 only if it was positive at a stan-
dard serum dilution of 1:40 for both BC3 and Sf9 mIFA
(with at least one antigen). To rule out the detection of
residual maternal antibodies, plasma of all HHV-8-sero-
positive children at 12 months who were born to HHV-8-
seropositive mothers was titered at birth, at 6 months,
and at 12 months. Primary infection event occurred
when previously seronegative children became seroposi-
tive at 12 months of age.
EBV serology
IgG antibodies against EBV viral capsid antigen (VCA)
were detected using a standard Enzyme Linked Immuno-
sorbent Assay kit. (ELISA) (Diagnostic Automation, Cali-
fornia). This commercially available kit is based on
recombinant purified protein of the VCA complex and
has a specificity and sensitivity of 100% as reported by the
manufacturer. Plasma was diluted 1:21 as per the manu-
facturer's instructions, and three calibrators and control
sera were tested in each test run. The optical density was
read on a microplate reader (Biotek instruments) at 450
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nm. Results were accepted when all the quality control
criteria were met as per the manufacturer's recommenda-
tion.
HIV-1 Test
All plasma was screened by a standard HIV-1 test kit
(Capillus HIV-1/2 Agglutination test kit, Trinity Biotech.)
and confirmed for HIV-1 antibodies by another standard
kit (Abbott Determine HIV-1/2 EIA, Abbott Laborato-
ries).
Statistical Analysis
Data was analyzed using the statistical software package,
SPSS version 17 (SPSS, Chicago, IL). Logistic regression
was used to test for significant associations between the
collected variables and serostatus at 12 months of age.
Univariate test of association was performed, and odds
ratio and 95% confidence intervals (CI) were calculated.
We also tested for interactions and multicollinearity by
checking the correlation between various variables. Mul-
tivariate analysis included all variables that had a p-value
≤ 0.05 to control for possible confounders and identify
independent associations.
Results
Study participants and prevalence of infection: For this
report, evidence of seroconversion for HHV-8 and EBV
was determined for 677 children when they reached 12
months of age. However, of these 677 children, 655 chil-
dren were also followed up at least once or more at 2, 4 or
6 months of age also. The remaining 22 children were fol-
lowed up directly at 12 months of age after enrollment at
birth. While analyzing factors associated with serocon-
version; 'ever' denotes that the child experienced that
condition at least once or more during the 12 month fol-
low-up period and 'never' denotes that the child was
never reported to experience that condition during any
follow-up visit. Follow-up information was collected
when the patient visited the clinic or by active follow-up
at the place of residence. At each follow-up visit, trained
nurses administered a structured questionnaire in order
to obtain information about the socio-economic status,
demographic data and medical history of the recruited
patients. The questionnaire data collected and analyzed
for this report is based on all prominent published studies
on HHV-8 prevalence and incidence. Data on socio-
demographic factors, ailments, illnesses or symptoms
Figure 1 Flowchart of study cohort. Flowchart summarizing the longitudinal cohort followed to study herpesviral infection in children in Lusaka, 
Zambia, 1998-2004. The present analysis includes 677 children who survived/returned at 12 months of age in order to establish reliable HHV-8, EBV 
and HIV-1 diagnosis.
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experienced, and information on any medications or
treatments received since the last visit were recorded
during these visits.
In the cohort of 12 month old Zambian children (N =
677), the prevalence of HHV-8+ EBV- children was
4.14%. We also observed that in this cohort the seroprev-
alence of EBV to be significantly higher than HHV-8. The
prevalence of HHV-8- EBV+ children was 49.63% dem-
onstrating that in this population a significantly larger
number of children were infected with EBV alone as com-
pared to HHV-8 alone (Figure 2). Prevalence of dually
infected (HHV-8+ EBV+) children was 9.30%.
Primary HHV-8 infection and associated clinical mani-
festations: Associations between primary HHV-8 infec-
tion and a range of socio-demographic characteristics
and medical characteristics indicative of the general
health of the child were evaluated (Table 1). In a univari-
ate analysis, a self-reported history of rashes was signifi-
cantly associated with primary HHV-8 infection (OR
1.84, 95% CI - 1.13-3.01). Also, children who were HIV-1
seropositive at 12 months of age (OR 4.79, 95% CI - 2.44-
9.38), were infected with EBV or were born to HIV-1
infected mothers had increased odds of primary HHV-8
infection as compared to those who were not. Multivari-
ate analysis indicated that HIV-1 seropositive status (at
18 months of age) was independently associated with pri-
mary HHV-8 infection (OR 3.69, 95% CI - 1.64-8.32).
After adjusting for confounders, we also observed a weak
association between history of rashes in children with
primary HHV-8 infection (OR 1.54, 95% CI- 0.92-2.56)
but no association with EBV infection. No other self-
reported clinical symptoms or socio-demographic char-
acteristics were significantly associated with primary
HHV-8 infection. These included self reported history of
all common medical conditions (fever, diarrhea, cough,
malaria, conjunctivitis, oral thrush) and indirect mea-
sures of the health of the child (use of antibiotics, hema-
tinics, multivitamins and administration of traditional
therapy).
Primary EBV infection and associated clinical manifes-
tations: We also compared the prevalence of primary
EBV infection and associated clinical characteristics in
the same cohort of 12 month old Zambian children
(Table 2). We observed that in a univariate analysis, self
reported rash was also associated with EBV infection in
children at 12 months (OR 1.56, 95% CI 1.06-2.3). Also,
other factors such as fever in the child, low education of
mother and HIV infection in the child or mother were
individually associated with EBV infection at 12 months.
Upon multivariate analysis, we observed that low educa-
tion of the mother and HIV infection in mother were
individually associated with EBV infection (OR 1.51, 95%
Figure 2 Prevalence of HHV-8 and EBV infection. Bar graph depicting the prevalence of HHV-8 and EBV positive children in 12 month old children 
(N = 677) in Lusaka, Zambia, 1998-2004.
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Table 1: Risk factors associated with primary HHV-8 infection.
Unadjusted Analysis Adjusted Analysisb
Positive/Total No.a p-value OR (95% CI) p-value OR (95% CI)
Socio-Demographic Characteristics
Gender
- Male 41/347 0.20 0.75 (0.48 - 1.17)
- Female 50/330 Reference
Ethnic Group
- Nyanja 45/308 0.17 1.47 (0.85 - 2.56)
- All others 25/167 0.19 1.52 (0.82 - 2.82)
- Bemba 21/202 Reference
Mothers Education
- 0-7 years 45/348 0.69 0.91 (0.59 - 1.42)
- 8 or more years 46/329 Reference
Mothers Employment
- Unemployed 78/566 0.60 0.85 (0.45 - 1.59)
- Employed 13/109 Reference
Monthly Income
- less than 100,000 ZMK 42/309 0.92 0.66 - 1.59)
- more than 100,000 ZMK 49/368 Reference
Household members
- 6 or more 32/247 0.80 0.94 (0.59 - 1.50)
- 2 to 5 57/418 Reference
HIV infection (mother)
- Positive 30/149 0.01 1.93 (1.19 - 3.12) 0.66 1.14 (0.63 - 2.08)
- Negative 61/528 Reference Reference
Child Characteristicsc
Birth weight of child
- less than 3.2 Kg 53/430 0.24 0.76 (0.49 - 1.20)
- more than 3.2 Kg 38/244 Reference
Diarrhea
- Ever 36/238 0.32 1.26 (0.80 - 1.99)
- Never 54/436 Reference
Fever
- Ever 38/270 0.65 1.11 (0.71 - 1.74)
- Never 52/404 Reference
Cough
- Ever 52/371 0.58 1.14 (0.73 - 1.78)
- Never 38/303 Reference
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CI 1.11-2.06 and OR 1.86, 95% CI 1.20-2.87, respectively).
As observed with HHV-8, no other self-reported clinical
symptoms (rashes, fever, diarrhea, cough, malaria, con-
junctivitis, and oral thrush), indirect measures of the
health of the child (use of antibiotics, hematinics, multivi-
tamins and administration of traditional therapy) and
socio-demographic characteristics were significantly
associated with primary HHV-8 infection.
Discussion
Very little is known about the clinical manifestations
associated with primary infection with HHV-8 in early
childhood and factors that may be associated with pri-
mary infection or an increase in risk of infection, espe-
cially in HIV-1 infected children, in an endemic region
such as Zambia. The majority of the seroprevalence stud-
ies are cross-sectional in design, making it difficult to
detect primary infection. Both HHV-8 and EBV are onco-
genic gamma-herpesviruses that have a similar mode of
transmission, most likely through saliva [9,10]. Therefore,
the major aim of this study was to investigate primary
HHV-8 and EBV infection, compare the clinical manifes-
tations associated with primary infection and whether
they have a similar mode of transmission and whether
there is an association between HHV-8 and EBV infec-
tion. Detailed analysis of these could provide important
information regarding the patterns of transmission, natu-
ral history of infection and the susceptible population at
higher risk for infection.
Our study has several strengths. We were able to ana-
lyze a well characterized cohort of children and their
caregivers. We also collected a wide range of data in the
form of questionnaires that were administered at each
follow-up visit. These questionnaires collected informa-
tion on most common symptoms and illnesses and any
information that may indirectly depict a poor health sta-
tus of the child. This study was conducted on children
from an established cohort of mother-child pairs
recruited at the University Teaching Hospital, the affili-
ated teaching hospital for the University of Zambia
Rashes
- Ever 28/143 0.01 1.84 (1.13 - 3.01) 0.10 1.54 (0.92 - 2.56)
- Never 62/531 Reference Reference
Malaria
- Ever 11/78 0.84 1.07 (0.54 - 2.12)
- Never 79/596 Reference
HIV infection (child)
- Positive 16/41 <0.001 4.79 (2.44 - 9.38) 0.002 3.69 (1.64 - 8.32)
- Negative 75/636 Reference Reference
EBV infection
- Positive 63/399 0.03 1.67 (1.04 - 2.69) 0.14 1.45 (0.89 - 2.36)
- Negative 28/278 Reference Reference
Antibiotics
- Ever 68/475 0.26 1.34 (0.81 - 2.24)
- Never 22/199 Reference
Traditional therapy
- Yes 12/61 0.13 1.68 (0.86 - 3.30)
- No 78/613 Reference
Multivitamin use
- Ever 7/32 0.15 1.89 (0.79 - 4.50)
- Never 83/642 Reference
OR- Odds Ratio, CI- Confidence Interval, ZMK- Zambian Kwacha.
aTotal number may not add up to 677 in all categories due to missing values.
bAdjusted analysis includes all variables with p-value ≤ 0.05 in the unadjusted analysis.
cData on lymphadenopathy, pneumonia, conjunctivitis, oral thrush and hematinics use in the child were also analyzed but not shown in this 
table.
Unadjusted and adjusted odds ratios to predict association between primary HHV-8 infection in a cohort of 677 children and socio-
demographic characteristics and medical conditions in Lusaka, Zambia, 1998-2004.
Table 1: Risk factors associated with primary HHV-8 infection. (Continued)
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Table 2: Risk factors associated with primary EBV infection.
Unadjusted Analysis Adjusted Analysisb
Positive/Total No.a p-value OR (95% CI) p-value OR (95% CI)
Socio-Demographic Characteristics
Gender
- Male 199/347 0.39 0.87 (0.64 - 1.19)
- Female 200/330 Reference
Ethnic Group
- Nyanja 182/308 0.88 1.03 (0.72 - 1.47)
- All others 99/167 0.87 1.04 (0.68 - 1.57)
- Bemba 118/202 Reference
Mothers 
Education
- 0-7 years 222/348 0.01 1.51 (1.11 - 2.06) 0.006 1.56 (1.14 - 2.13)
- 8 or more 
years
177/329 Reference Reference
Mothers 
Employment
- 
Unemployed
331/566 0.56 1.13 (0.74 - 1.72)
- Employed 61/109 Reference
Monthly Income
- less than 
100,000 ZMK
189/309 0.28 1.18 (0.87 - 1.61)
- more than 
100,000 ZMK
210/368 Reference
Household 
members
- 6 or more 148/247 0.74 1.06 (0.77 - 1.45)
- 2 to 5 245/418 Reference
HIV infection 
(mother)
- Positive 108/149 <0.001 2.15 (1.44 - 3.2) 0.005 1.86 (1.20 - 2.87)
- Negative 291/528 Reference Reference
Child Characteristicsc
Birth weight of 
child
- less than 3.2 
Kg
251/430 0.72 0.95 (0.69 - 1.29)
- more than 
3.2 Kg
147/244 Reference
Diarrhea
- Ever 140/238 0.98 0.99 (0.72 - 1.37)
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School of Medicine in Lusaka, Zambia to study the epide-
miology and transmission of HHV-8 in a population that
is an endemic area for HHV-8 infection. Our results
clearly show that children are infected by both HHV-8
and EBV very early in life. HHV-8 and EBV have been
reported to have similar modes of transmission, via
saliva. Interestingly, our results show that the incidence of
EBV early in childhood is significantly higher as com-
pared to HHV-8. A very similar seroprevalence rate has
been reported for EBV in some Asian countries such as
India, where Venkitaraman et al have reported that IgG
antibodies to VCA rose rapidly to 90% by 5 years of age
[11]. The prevalence of VCA-specific IgM and the geo-
metric mean titer of VCA-specific IgG antibodies were
highest between the ages of 6 months and 2 years, the
median age of primary infection being 1.4 years. Primary
infection in Malaysian children reportedly occurs at 4-6
months. Thus the transmission for EBV is either more
effective or occurring at a much higher rate as compared
to HHV-8, possibly as a result of more frequent exposure.
Indeed, a recent study from Uganda has reported that the
- Never 257/436 Reference
Fever
- Ever 168/270 0.15 1.26 (0.92 - 1.72)
- Never 229/404 Reference
Cough
- Ever 214/371 0.48 0.89 (0.66 - 1.22)
- Never 183/303 Reference
Rashes
- Ever 96/143 0.02 1.56 (1.06 - 2.3) 0.08 1.43 (0.96 - 2.13)
- Never 301/531 Reference Reference
Malaria
- Ever 48/78 0.61 1.13 (0.7 - 1.84)
- Never 349/596 Reference
HIV infection 
(child)
- Positive 63/91 0.03 1.67 (1.04 - 2.69) 0.14 1.44 (0.88 - 2.36)
- Negative 336/586 Reference Reference
EBV infection
- Positive 33/41 0.01 3.04 (1.38 - 6.69) 0.27 1.64 (0.67 - 3.90)
- Negative 41/636 Reference
Antibiotics
- Ever 273/475 0.24 0.82 (0.58 - 1.15)
- Never 124/199 Reference
Traditional 
therapy
- Yes 40/61 0.27 1.37 (0.79 - 2.37)
- No 357/613 Reference
Multivitamin use
- Ever 20/32 0.67 1.17 (0.56 - 2.44)
- Never 377/642 Reference
OR- Odds Ratio, CI- Confidence Interval, ZMK- Zambian Kwacha.
aTotal number may not add up to 677 in all categories due to missing values.
bAdjusted analysis includes all variables with p-value ≤ 0.05 in the unadjusted analysis.
cData on lymphadenopathy, pneumonia, conjunctivitis, oral thrush and hematinics use in the child were also analyzed but not shown in this 
table.
Unadjusted and adjusted odds ratios to predict association between primary EBV infection in a cohort of 677 children and socio-demographic 
characteristics and medical conditions in Lusaka, Zambia, 1998-2004.
Table 2: Risk factors associated with primary EBV infection. (Continued)
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detection of EBV DNA in saliva was more frequent than
HHV-8 DNA [12].
Both EBV and HHV-8 have been reported to have simi-
lar modes of transmission via salivary contact, low socio-
economic status and overcrowded living conditions have
been considered as a risk factor for acquiring both HHV-
8 and EBV. A study conducted on Ugandan children
found a direct association of HHV-8 infection with low
socio-economic status and the use of surface water [13].
In our study socio-demographic information was col-
lected at birth and data on recent medical history pro-
vided by the caregiver, which may directly or indirectly
help in assessing the health of the child, were collected at
each follow-up visits. We did not observe any association
of primary infection with HHV-8 with the reported
socio-economic characteristics, including monthly
income, mother's educational level, household size or
ethnicity. However, direct comparison of different HHV-
8 serological studies can be difficult sometimes because
of different serological tests that are used for diagnosis of
HHV-8 infection, the difference in the age of the children
and study cohort. As expected, we did observe that pri-
mary infection with EBV was significantly increased in
children whose mothers had 7 years or less of education.
However, assessing socio-economic status is complex and
our questionnaire was not designed to examine direct
markers of socio-economic status, therefore the collected
information can only provide indirect information about
the socio-economic status of the household.
We also analyzed a range of child characteristics that
may be associated with HHV-8 and EBV infection in chil-
dren, and found that HIV-1 infection was found to be a
major risk factor. Our earlier studies have found that
HIV-1 infected children were more likely to be infected
with HHV-8 [7]. Interestingly, unlike HHV-8 we did not
find HIV-1 infection risk to be risk factor for EBV infec-
tion and we did not find a correlation between EBV and
HHV-8 infection in this group of children. These results
also show that in the case of EBV the immune status of
the child may not be an important factor and that most
children in this cohort, regardless of their HIV-1 status,
will get infected early in life. In fact, by 2 years of age, we
observed that the seroprevalence for EBV was 92% in the
same cohort (data not shown). It is possible that for
HHV-8, the immune status of the child plays a more sig-
nificant role while in case of EBV it is the status of the
transmitters that is more important. Multivariate analysis
showed that HIV-1 infection in mothers was associated
with higher risk of EBV infection in children as compared
to children born to HIV-1 uninfected mothers. This is
most likely because the HIV-1 positive mothers are more
likely to have higher EBV viral loads and thus shed more
virus in their saliva as compared to HIV-1 negative moth-
ers [14]. Another study, conducted in Canada, has
reported similar results where children born to HIV-1
infected mothers seroconverted earlier for EBV, than
children born to HIV-1 uninfected mothers [15]. Lack of
availability of HAART at the time of this study may have
resulted in a high level of transmission of HIV-1 to chil-
dren but its impact on HHV-8 and EBV transmission is
hard to estimate. It is clear that these viruses interact with
HIV that predisposes HIV-infected individuals to malig-
nancies. In general, while the risk of developing non-
Hodgkins lymphomas in AIDS patients in Africa is lower
as compared to United States, it is thought to be associ-
ated with severe immunosuppression, poor prognosis
and shorter mean survival of the African patients [16-18].
Our data suggests that children who were reported to
have had rashes were more likely to seroconvert for
HHV-8. Presence of rashes was marginally associated
with infections with both HHV-8 and EBV. In fact, pri-
mary HHV-8 infection has been reported to be associ-
ated with the presence of maculopapular rash [6]. In our
study the association was not as strong but it could have
been due to difference in population sampling. In the
study reported by Andreoni et al children admitted to the
emergency ward were sampled which could have biased
the study towards observing more severe cases [6]. In our
study the follow-up questionnaire did not distinguish
between various kinds of rashes; therefore, it is difficult
for us to determine an association with a specific type of
rash. Overall, appearance of rashes may be indicative of
primary infection with either one or both of these infec-
tions and a larger sample size would be necessary to
examine this association further. Malaria is also endemic
in Zambia and we did not find any association between
seroconversion for either EBV or HHV-8 with a recent
history of malaria. While malaria may not be a risk factor
for seroconversion to either virus, a recent study has sug-
gested that EBV and malaria may act synergistically in the
pathogenesis of childhood Burkitt lymphoma [19], most
likely through the direct reactivation of the virus [20,21].
Our study has several limitations. Firstly, reporting or
recall bias leading to exposure misclassification could not
be entirely ruled out. In a majority of the cases, the chil-
dren came back with the caregivers multiple times during
the 12 month period. This allowed us to document clini-
cal symptoms at regular intervals. But 22 children came
directly at 12 months after their enrollment at birth. This
could have led to an underreporting of clinical symptoms
from which a child may have suffered. Secondly, it has
been reported by Mbulaiteye et al that households with
limited access to water may increase the risk for HHV-8
infection [13]. Whether it increases the risk for HHV-8 or
EBV primary infection in early childhood could not be
analyzed in the present study because this data was not
collected. Third, we cannot exactly pinpoint as to when
the primary infection event for HHV-8 or EBV took place
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during the 12 month period. Therefore, it is difficult to
argue that associated symptoms could be attributed
entirely to either EBV or HHV-8 seroconversion. The
number of children who were seropositive for HHV-8 or
EBV alone was small to draw decisive conclusions. Lastly,
we cannot rule out that the associated symptoms were
entirely due to primary seroconversion and not due to
reactivation of HHV-8. However, based on our previous
study it is likely that children under 12 months of age are
usually undergoing primary HHV-8 infection.
While a large percentage of children will eventually
become infected by EBV and as we have reported earlier
that there is a steady increase in HHV-8 infection in early
childhood with age in Zambia, the impact of these infec-
tions on the population in the context of HIV-1 infection
is not clear. It is possible that the infection by one or both
of the viruses may increase the susceptibility to HIV-1
infection or vice versa, as we have observed a significant
co-relation between HIV-1 and the two viruses. It is pos-
sible that dual infection may affect the disease progres-
sion because it has been reported that HHV-8 and EBV
may interact at the molecular level and may promote the
establishment of latency [22]. Therefore, a better under-
standing of the interaction between these viruses may
lead to the development of better strategies to manage
these infections and also in prevention of infection in
early childhood.
Conclusions
Taken together these results suggest that there is no cor-
relation between primary HHV-8 and EBV infection. Pri-
mary infection with HHV-8 may clinically present as rash
but remains largely asymptomatic in early childhood in
Zambia. Because of mild and non-descript symptoms
associated with primary infection of HHV-8, it may
remain undetected or untreated in this population. Our
results also suggest that HIV-1 infection of the mother
may be associated with increased risk of EBV infection
for the child. HIV-1 infected children are significantly
more likely to acquire HHV-8 infection as compared to
HIV-1 uninfected children.
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